Balchem Corporation has announced impressive financial results for the third quarter of 2026, showcasing a robust performance that underscores its growth strategy in the chemicals and allied products sector.
On October 23, 2026, the company reported net sales of $290.7 million for the quarter ending September 30, 2026. This represents an 8.6% increase from the same quarter last year. Additionally, Balchem's net earnings reached $46.7 million, a 16% rise year-over-year, and adjusted EBITDA was reported at $80.3 million, up 12.4% compared to the prior year.
“Balchem delivered another excellent quarter, with healthy growth across all three of our reporting segments and record consolidated quarterly net sales, net earnings, and adjusted EBITDA,” said Ted Harris, Chairman, President, and CEO of Balchem.
Background
Balchem Corporation, incorporated in Maryland, operates under the SIC code 2800, which covers Chemicals & Allied Products. It trades on the Nasdaq under the ticker BCPC. The company specializes in human nutrition, animal nutrition, and specialty products. Recent filings indicate a consistent focus on growth and shareholder value.
What the Filing Says
The filing details the company's financial performance, stating that “the information in this Form 8-K shall not be deemed ‘filed’ for purposes of Section 18 of the Securities Exchange Act of 1934.” The press release attached as Exhibit 99.1 provides further insights into the financial results.
Impact
Balchem's strong performance may positively influence its stakeholders, including investors and employees. The results may also affect competitors in the chemicals sector, who will need to assess their strategies in light of Balchem's growth and innovation.
What's Next
The filing does not specify what happens next, but the company is expected to continue its strategic initiatives and showcase its latest innovations at upcoming industry events.
Source: SEC Filing Accession Number 0000009326-26-000032